Protalix BioTherapeutics (PLX) Leases (2019 - 2026)

Protalix BioTherapeutics has reported Leases for 8 years, with the latest figure at $7.8 million in Q1 2026.

• For the quarter ending Q1 2026, Leases rose 49.15% year-over-year to $7.8 million; the trailing twelve-month figure through Mar 2026 stood at $7.8 million (up 49.15% YoY), and the FY2025 full-year result was $7.7 million, up 41.8% from the prior year.
• Leases for Q1 2026 stood at $7.8 million, up from $7.7 million in the prior quarter.
• The five-year high for Leases was $7.8 million in Q3 2025, with the low at $4.8 million in Q2 2022.
• Average Leases over 5 years is $5.8 million, with a median of $5.6 million recorded in 2024.
• Year-over-year, Leases decreased 12.79% in 2025 and surged 49.15% in 2026.
• Tracing PLX's Leases over 5 years: stood at $5.1 million in 2022, then advanced by 16.16% to $5.9 million in 2023, then retreated by 8.11% to $5.4 million in 2024, then jumped by 41.8% to $7.7 million in 2025, then advanced by 1.21% to $7.8 million in 2026.
• The last three Leases figures came in at $7.8 million (Q1 2026), $7.7 million (Q4 2025), and $7.8 million (Q3 2025), per Business Quant data.

Peer Comparison